# Prebiotics Constipation Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/prebiotics-constipation-meta-analysis-evidence-review
Category: evidence-review
Summary: Prebiotics Constipation Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are m
Last reviewed: 2026-05-28
Reviewed by: Migaku Evidence Review
# Prebiotics Constipation Meta-analysis: What the Evidence Says

## Quick Answer

Prebiotics Constipation Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 narrative review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions | narrative review | 3 | 2026-02-27 | 10.3390/antibiotics15030251 |
| Research progress and controversies in the treatment of functional constipation-related depression with probiotics and prebiotics: a narrative review | preclinical study | 4 | 2026-02-13 | 10.3389/fphar.2026.1735614 |

## What The Sources Report

- Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities. [Šuran Jelena (2026); evidence level 3]
- Early studies reported SIBO in up to 60-78% of IBS cases based on lactulose breath testing, though later investigations using more rigorous methods found lower prevalences (e.g., 4-20%). [Šuran Jelena (2026); evidence level 3]
- Gut microbiota dysbiosis is recognized as a common key link: patients with both constipation and depression often exhibit reduced microbial diversity, decreased short-chain fatty acids (SCFAs), lower abundance of probiotic genera (e.g., Bifidobacterium,), and heightened inflammation (;;;;;;;). [Dai Qiuhua (2026); evidence level 4]
- Despite generally high safety profiles, existing clinical evidence remains controversial due to significant heterogeneity and uncertain efficacy, and the underlying mechanisms remain unclear (;;;). [Dai Qiuhua (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For prebiotics constipation meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Šuran Jelena (2026). IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions. DOI: 10.3390/antibiotics15030251. PMCID: PMC13023761. PMID: 41892413. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13023761/
- Dai Qiuhua (2026). Research progress and controversies in the treatment of functional constipation-related depression with probiotics and prebiotics: a narrative review. DOI: 10.3389/fphar.2026.1735614. PMCID: PMC12946840. PMID: 41769687. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12946840/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.